PRM1 and colorectal carcinoma: Cancer vaccine composed of PRM1 epitope may facilitate tumor control by induction of specific immune response, since we have demonstrated that anti-PRM1 can be used as an antagonist of secreted PRM1 to inhibit CRC tumorigenesis and cell proliferation.